Table 1 Clinical information of completer (n = 11) and all randomized patients (n = 20, completer and drop-outs)

Age [years]^a

47 (19–62)

56 (32–63)

55 (47–63)

Sex [n] male:female

5:1

3:2

14:6

BMI [kg/m²]^a

26 (20–28)

26 (22–28)

26 (25–27)

 AML

1

4

8

 ALL

1

0

1

 APL

1

0

1

 NHL

2

0

5

 HL

0

0

1

 t-cell lymphoma

1

0

1

 MW

0

0

1

 MM

0

1

1

 PMF

0

0

1

 ED

1

3

7

 SD

0

1

2

 PD

1

0

1

 CR

0

1

2

 PR

0

0

1

 recurrence

2

0

5

 N/A

2

0

2

Time since initial diagnosis [weeks]^a

46 (2–371)

6 (2–215)

32 (7–128)

Cycles of chemotherapy before admission [n]^a

9 (0–16)

1 (0–9)

4 (1–9)

 High-dose prior to autologous HSCT

1

1

5

 Induction therapy for AML

4

3

8

 Intensive chemotherapy for ALL, HL, NHL

1

1

7

Duration of hospitalization [days]^a

27 (21–56)

27 (16–69)

26 (22–34)

Karnofsky performance index [%]^a

95 (80–100)

90 (80–100)

90 (85–90)